

## Agile Therapeutics Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 27-Apr-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

# Agile Therapeutics Inc

## COMPANY OVERVIEW

Company Name	Agile Therapeutics Inc
Parent Company Name	Agile Therapeutics Inc
Website	<a href="http://www.agiletherapeutics.com/">http://www.agiletherapeutics.com/</a>
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	0
Number of Patents as Owner	8
Number of Patents as Third Party	2
Number of Deals	2
Key Indications	Female contraception, Depression, Parkinsons disease, Alzheimers disease, Central nervous system disease, Migraine, Nausea, Pain
Key Target-based Actions	Progesterone receptor agonist, Estrogen receptor agonist, 5-HT 3 receptor antagonist, MAO B inhibitor
Key Technologies	Patch formulation, Transdermal formulation, Small molecule therapeutic, Absorption enhancer transdermal, Drug combination, Formulation preservation, Absorption enhancer, Controlled release formulation, Matrix

## COMPANY PROFILE

### SUMMARY

Agile Therapeutics, founded in 1997, is a late-stage, privately-held pharmaceutical company focusing on women's health products.

### FINANCIAL

In February 2015, a first tranche of \$16.5 million was funded upon execution of the loan agreement and \$15.5 million would be used to repay Agile's existing term loan facility. Under the terms of the loan agreement, Agile was not obligated to draw an additional tranche of up to \$8.5 million prior to July 1, 2016, subject to the achievement of certain clinical milestones, which may be extended to December 31, 2016. At that time, Agile issued Hercules a warrant to purchase 180,274 shares of Agile common stock at an exercise price of \$5.89 each.

In January 2015, the company entered into a definitive stock purchase agreement with a group of institutional accredited investors for the private placement of 3.4 million of common stock shares at \$5.85 per share and the gross proceeds were expected to be \$20 million. At that time, the private placement was expected to close on or about January 23, 2015. Later that month, the company raised net proceeds of approximately \$19.3 million.

In June 2014, the company's stock was added to the Russell Microcap Index.

In March 2014, Agile filed form S-1 with the US SEC for a proposed IPO of common stock. In May 2014, the company priced the offering of 9,166,667 shares at \$6 per share. The underwriters were granted a 30-day option to buy up to an aggregate of 1,375,000 additional shares of common stock, to cover any over-allotments. The offering was expected to close on May 29, 2014. At that time, the shares were expected to initiate trading on the NASDAQ Global Market, on May 23, 2014, under the symbol "AGRX".

In January 2013, the company closed a term loan facility for up to \$15 million with Oxford Finance.

In July 2012, the company raised \$40 million from a series C financing.

In June 2010, Agile raised \$45 million from a series B preferred stock financing.

In December 2007, Agile raised \$5.6 million from a series E financing round.

[Return to Table of Contents](#)



COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	12.10
Change (USD)	-0.67 (-5.25%)
Previous Close Price (USD)	12.77
Volume	66,331
52-Week High (USD)	13.19
52-Week Low (USD)	5.05
Date	27-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	18,634,872
Current Market Capitalization	282,911,241
EPS (Date Reported)	-1.41093

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

[Return to Table of Contents](#)


Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
ProQuest Associates IV LLC	Investment Advisor	United States	4,668,663	21.07	811,966	0.21	23-Jan-2015
Aisling Capital, LLC	Private Equity	United States	2,983,797	13.47	811,966	0.37	23-Jan-2015
RA Capital Management, LLC	Hedge Fund	United States	1,458,792	6.58	1,458,792	1	23-Jan-2015
Royce Micro-Cap Fund	Mutual Fund	United States	190,882	0.86	0	0	31-Mar-2015
Granahan Investment Management, Inc.	Investment Advisor	United States	182,020	0.82	182,020	1	31-Mar-2015
Royce Capital Fund - Micro-Cap Portfolio	Mutual Fund	United States	180,500	0.81	0	0	31-Mar-2015
Altomari (Alfred F)	Individual Investor	United States	75,754	0.34	17,500	0.3	11-Mar-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	24,717	0.11	0	0	28-Feb-2015
iShares Micro-Cap ETF	Mutual Fund	United States	25,442	0.11	1,277	0.05	31-Mar-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	17,711	0.08	800	0.05	31-Mar-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	3,800	0.02	1,300	0.52	28-Feb-2015
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	3,497	0.02	0	0	28-Feb-2015
Fidelity Spartan Total Market Index Fund	Mutual Fund	United States	2,699	0.01	2,699	1	28-Feb-2015
Vanguard US Equity Index Fund	Mutual Fund	United States	1,600	0.01	1,600	1	28-Feb-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	1,507	0.01	0	0	28-Feb-2015
Guggenheim Investments	Investment Advisor/Hedge Fund	United States	1,598	0.01	7	0	31-Mar-2015
Wilshire Micro-Cap ETF	Mutual Fund	United States	1,598	0.01	7	0	31-Mar-2015

[Return to Table of Contents](#)



Creative Planning, Inc.	Investment Advisor/ Hedge Fund	United States	0	0	-50	-1	31-Mar-2015
-------------------------	-----------------------------------	---------------	---	---	-----	----	-------------

## FINANCIAL PERFORMANCE



	2012	2013	2014		
<b>Sales (USD M)</b>	0	0	0		
<b>Operating Income (USD M)</b>	-23.316851	-12.728377	-18.515216		
<b>Net Income (USD M)</b>	-23.860127	-14.32062	-16.077468		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	0	-6.523995	-6.844998
2014 Q3	0	-6.048884	-6.353362
2014 Q2	0	-3.49471	-3.718401
2014 Q1	0	-2.447626	0.839293
2013 Q3	0	-3.321389	-3.690955
2013 Q2	0	-3.24907	-3.619879
2013 Q1	0	-4.228361	-4.605416

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	20.013754	2.119646	40.182141		
Inventories - Total	0	0	0		
Current Assets - Total	20.267857	2.26635	40.985916		
Property, Plant And Equipment - Net	7.029576	11.963079	12.046267		
Other Assets - Total	0.220707	0.175707	1.794043		
Total Assets	27.51814	14.405136	54.826226		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	1.126931	0.715454	2.631217		
Short Term Debt & Current Portion Of Long Term Debt	0	5.105407	5.003143		
Current Liabilities - Total	2.106854	6.844503	8.992521		
Long Term Debt	14.787024	9.769528	9.827758		
Other Liabilities	0	0	0		
Total Liabilities	16.893878	16.614031	18.820279		

[Return to Table of Contents](#)

## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	69.232677	70.81569	0		
Common Stock	0.000004	0.000088	0.001864		
Treasury Stock	0		0		
Total Liabilities & Shareholders' Equity	27.51814	14.405136	54.826226		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.43	-1.5	-1.46
31-Dec-2016	-1.2	-1.56	-1.47
31-Dec-2017	-0.8	-0.32	0.1

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-31.76	0
31-Dec-2016			-29.22	0
31-Dec-2017			-19.51	36.93


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Prophylaxis	3	0	3
Gynecology and obstetrics	3	0	3

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Pre-registration	1
Phase 2 Clinical	1
Discovery	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Gynecology and obstetrics	0	4
Prophylaxis	0	4

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 3	1	4
Phase 2	0	3
Phase 1	0	4

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Gastrointestinal disease	0	1	1
Degeneration	0	1	1
Psychiatric disorder	0	2	2
Neurological disease	0	2	2
Prophylaxis	11	0	11
Gynecology and obstetrics	11	0	11

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile

<b>Drug Name</b>	ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile
<b>Key Synonyms</b>	Twirla
<b>Originator Company</b>	Agile Therapeutics Inc
<b>Active Companies</b>	Agile Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Pre-registration
<b>Active Indications</b>	Female contraception
<b>Target-based Actions</b>	Progesterone receptor agonist, Estrogen receptor agonist
<b>Other Actions</b>	Female contraceptive
<b>Technologies</b>	Drug combination, Transdermal formulation, Patch formulation, Absorption enhancer transdermal, Small molecule therapeutic
<b>Last Change Date</b>	25-Feb-2015

### levonorgestrel (Skinfusion patch, female contraception), Agile

<b>Drug Name</b>	levonorgestrel (Skinfusion patch, female contraception), Agile
<b>Key Synonyms</b>	levonorgestrel
<b>Originator Company</b>	Agile Therapeutics Inc
<b>Active Companies</b>	Agile Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Female contraception
<b>Target-based Actions</b>	Progesterone receptor agonist
<b>Other Actions</b>	Female contraceptive
<b>Technologies</b>	Transdermal formulation, Patch formulation, Small molecule therapeutic
<b>Last Change Date</b>	09-Apr-2014

[Return to Table of Contents](#)



undisclosed patch programs (female contraception), Agile Therapeutics

Drug Name	undisclosed patch programs (female contraception), Agile Therapeutics
Key Synonyms	
Originator Company	Agile Therapeutics Inc
Active Companies	Agile Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Female contraception
Target-based Actions	
Other Actions	Contraceptive, Unspecified drug target
Technologies	Transdermal formulation, Patch formulation, Absorption enhancer transdermal, Small molecule therapeutic
Last Change Date	17-Mar-2014



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

